

14 Aug 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Wegovy's solid new trial results; Lilly's sales swing back; nothing off the table for new Bayer boss; new compliance crackdown in China; and McKinsey on AI.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 11 August 2023, including: Wegovy's solid new trial results; [Eli Lilly and Company's](#) sales swing back; nothing off the table for new [Bayer AG](#) boss; new compliance crackdown in China; and McKinsey on AI.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[SELECT: Novo Nordisk Comes Roaring Back](#)" - Scrip, 8 Aug, 2023.)

(Also see "[Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede](#)" - Scrip, 9 Aug, 2023.)

(Also see "[Nothing Off The Table For New Bayer Boss](#)" - Scrip, 8 Aug, 2023.)

(Also see "[Storm Coming? Commercial Compliance Crackdown Shocks China Pharma Industry](#)" - Scrip, 8 Aug, 2023.)

(Also see "[McKinsey Exec On Generative AI in R&D And Pharmacovigilance, Digital Twins](#)" - Scrip, 7 Aug, 2023.)

[Click here to explore this interactive content online](#) 